The specter of generic rivalry has consistently loomed above copyright’s iconic drug, PDE5 Inhibitor, triggering questions about the outlook of connected drug investments. While first periods saw significant gains, the intellectual property expiration has allowed the door for discounted copies, likely lowering profitability and presenting a signi